ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development
Betsy Goodfellow | December 7, 2023 | News story | Research and Development | NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership
ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies.
The partnership is intended to explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK bispecific antibody.
The companies plan to assess various combination therapies in preclinical cancer models in 2024 before starting clinical trials.
Dr Daniel Teper, NAYA’s chief executive officer, commented: “We are impressed with the data ONK has generated using its differentiated editing of NK cells, which may further enhance the efficacy of our FLEX-NK bispecific antibodies. The future development of this combination therapy alongside our monotherapy clinical trials will help expand patient options and narrow the gap towards improving the long-term survival of patients with hepatocellular carcinoma.”
Chris Nowers, ONK’s chief executive officer, added: “The opportunity to partner with NAYA to evaluate the activity of our optimally gene-edited, non-CAR directed, allogeneic NK cell therapies in combination with its exciting FLEX-NK bispecific antibodies offers an opportunity to further improve response rates and durability of NK cell therapy. We believe this therapeutic combination represents a broadly applicable and versatile approach to treat patients with cancer and autoimmune diseases, where additional treatment options are needed.”
Betsy Goodfellow
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
PM Society and CIM launch new leadership programme for pharma marketers
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to …
